At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 203 enrolled
Drug / intervention
Ketorolac 30 mg IV +1 moredrug
Likely dose
Ketorolac 30 mg IVfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Perioperative Ketorolac in High Risk Breast Cancer Patients With and Without Inflammation. A Prospective Randomized Placebo-controlled Trial.
In Brief
A Phase 3 clinical trial evaluating Ketorolac 30 mg IV and Placebos for Curative Breast Cancer Surgery and 2 related conditions. Completed, enrolled 203 participants across 1 site.
Detailed Summary
Do the use of Ketorolac in one intravenous injection at the moment of the operative incision reduce the number of recurrence in patient with advanced breast cancer without inflammation signs.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCurative Breast Cancer Surgery, Inflammatory Positive/Negative Status, Pre Surgical Incision Administration
CountriesBelgium
CollaboratorsAnticancer Fund, Belgium
Timeline
Phase 3CompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartFeb 2013
First PostedMar 2013
Primary CompletionOct 2015
Study CompletionSep 2018
TodayJul 2026
First PostedMar 7, 2013
Enrollment StartFeb 1, 2013
Primary CompletionOct 1, 2015
Study CompletionSep 1, 2018
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 13.3 years ago
Interventions
Ketorolac 30 mg IVdrug
Active drug
Placebosdrug
Placebo looking like the Active drug